ArticlePLOS global public health2024
Post-tuberculosis lung disease: Addressing the policy gap.
Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of pulmonary rehabilitation on lung function and quality of life in pulmonary tuberculosis survivors with post-tuberculosis lung disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Prevalence and associated factors of post-tuberculosis lung disease in Sub-Saharan Africa: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Diverging Trends in Home Respiratory Care in an Aging Society: National Data from Japan.JMA journal · 2026Article
- HIV-Associated Pulmonary Arterial Hypertension in Resource-Limited Settings: A "Forgotten" Diagnosis, a Great Imitator, and a Multi-Hit Pulmonary Vasculopathy.Pulmonary circulation · 2026Review
- Systemic Gaps and Roadmap for Integrated Care for Post-tuberculosis Lung Disease in Ethiopia: A Narrative Review.Cureus · 2026Review
- Long-term risk of death after tuberculosis diagnosis and treatment.Nature medicine · 2026Article
- Early interventions reduce multimorbidity and TB disability in Kenya, Uganda, Zambia, and Zimbabwe.IJTLD open · 2026Article
- Post-TB care in the UK: a national survey of existing practice.BMJ open respiratory research · 2026Article
- Post-tuberculosis lung disease.Breathe (Sheffield, England) · 2026Review
- Rehabilitation for individuals with post-tuberculosis lung disease.Breathe (Sheffield, England) · 2026Review
- Effect of home-based pulmonary rehabilitation on ventilation dynamics and small airway dysfunction in people with post-tuberculosis lung disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Post-TB sequelae and care: a systematic review and synthesis of qualitative research.IJTLD open · 2025Article
- Post-treatment Lung Tuberculosis Sequelae: an Inexpensive Clinical-Laboratory Nomogram to Predict Tissue Destruction.Mediterranean journal of hematology and infectious diseases · 2025Article
- Correlations between exercise oxygen consumption, lung function, image findings, and quality of life in adults with post-tuberculosis lung disease.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of long-term functional impairment following curative treatment for tuberculosis (TB) constitutes a significant global health problem. By some estimates, chronic respiratory impairment, or post-tuberculosis lung disease (PTLD), is present in just over half of all patients who have completed TB therapy. Despite this high prevalence and substantial associated morbidity, discussion of PTLD is essentially absent from international and national TB policies and guidelines. Clear and ambitious clinical standards should be established for the diagnosis and management of PTLD, including the stipulation that all patients completing TB therapy should be screened for PTLD. Patients diagnosed with PTLD should receive linkage to chronic care, with access to inhalers and home oxygen, as indicated based on individual symptoms and pathophysiology. Leveraging their considerable influence, major funders, such as The Global Fund, could help close the gap in PTLD care by including PTLD in their strategic vision and funding streams. Immediate action is needed to address the substantial burden of disease associated with PTLD. This will require expanding the global approach to TB to include a commitment to diagnosing and treating long-term complications following initial curative therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.